このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

腰椎神経根症患者におけるテカール療法:無作為化比較試験

2026年11月11日 更新者:Izmir City Hospital

腰部神経根症患者に対するテカール療法、従来の理学療法、および偽治療の有効性:ランダム化比較試験

Lumbar radiculopathy is a common cause of low back and leg pain, most frequently resulting from lumbar disc herniation and nerve root irritation. Conservative management, including physical therapy modalities and exercise therapy, is generally recommended as first-line treatment for patients without progressive neurological deficits. Tecar therapy (Transfer of Energy Capacitive and Resistive) is a non-invasive electrotherapeutic modality that delivers high-frequency electromagnetic energy to deep tissues and has been proposed to reduce pain, enhance microcirculation, and promote tissue recovery. However, evidence regarding its effectiveness in lumbar radiculopathy remains limited.

The aim of this randomized controlled trial is to evaluate the efficacy of Tecar therapy in patients with lumbar radiculopathy and to compare its clinical effects with conventional physical therapy and sham Tecar treatment.

A total of 90 participants with unilateral L5 and/or S1 radiculopathy will be randomized into three groups: (1) conventional physical therapy, (2) Tecar therapy combined with standard physical therapy, and (3) sham Tecar therapy combined with standard physical therapy. All participants will receive standardized postural education and a home exercise program.

The primary outcome will be radicular leg pain intensity measured by the Visual Analog Scale (VAS) at Week 2. Secondary outcomes will include low back pain intensity (VAS), functional disability (Oswestry Disability Index), neuropathic pain characteristics (PainDETECT questionnaire), lumbar mobility (Modified-Modified Schober Test), nerve root irritability (Straight Leg Raise test), rescue analgesic consumption, and exercise adherence. Outcomes will be assessed at baseline, post-treatment (week 2), and follow-up visits at weeks 6 and 12.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

This assessor-blinded, randomized controlled trial will be conducted in the Department of Physical Medicine and Rehabilitation at İzmir City Hospital, a tertiary-level outpatient center. The study will be designed and reported according to CONSORT recommendations.

Participants aged 18-65 years with clinically diagnosed unilateral L5 and/or S1 radiculopathy and symptom duration between 6 weeks and 6 months will be eligible. Diagnosis will primarily be based on clinical findings consistent with radiculopathy, including dermatomal leg pain and supportive neurological examination findings, while lumbar MRI and/or EMG will be used as confirmatory evidence. After written informed consent is obtained, eligible participants will be randomly assigned in a 1:1:1 ratio to one of three groups using computer-generated randomization with concealed allocation.

Group 1 will receive conventional physical therapy consisting of hot pack, continuous ultrasound therapy, and transcutaneous electrical nerve stimulation (TENS). Group 2 will receive Tecar therapy in addition to standardized base therapy. Tecar treatment will include capacitive and resistive energy transfer applied to the lumbar paraspinal region and gluteal muscles. Group 3 will receive sham Tecar therapy using the same procedure as the active Tecar protocol but with zero energy output. All groups will additionally receive standardized postural education and a home exercise program.

Outcome assessments will be performed by an independent physiatrist blinded to group allocation at four time points: baseline, post-treatment (week 2), and follow-up visits at weeks 6 and 12. The primary outcome will be change in radicular leg pain intensity from baseline to Week 2, measured by the Visual Analog Scale (VAS). Secondary outcomes will include low back pain intensity (VAS), functional disability (Oswestry Disability Index), neuropathic pain features (PainDETECT questionnaire), lumbar mobility (Modified-Modified Schober Test), nerve root irritability assessed with the Straight Leg Raise test, rescue analgesic consumption, and exercise adherence.

The study aims to determine whether Tecar therapy provides additional clinical benefit over conventional physical therapy and to evaluate the effectiveness of Tecar therapy beyond placebo effects using a sham-controlled design.

研究の種類

介入

入学 (推定)

90

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

      • Izmir、トルコ(Türkiye)、35000
        • 募集
        • İzmir City Hospital
        • コンタクト:
      • Izmir、トルコ(Türkiye)
        • 募集
        • İzmir Cİty Hospital
        • コンタクト:
          • Ertan Yilmaz, Medical Doctor, Specialist
          • 電話番号:+905318431901
          • メール:ertnyilmzz@gmail.com

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~65年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Adults aged 18-65 years
  • Clinical diagnosis of unilateral L5 and/or S1 lumbar radiculopathy
  • Symptom duration between 6 weeks and 6 months
  • Average radicular pain intensity ≥3 on the Visual Analog Scale (VAS) during the previous month
  • Availability of lumbar MRI and/or EMG performed within the previous 6 months
  • Willingness to participate and ability to provide written informed consent

Exclusion Criteria:

  • Bilateral lumbar radiculopathy
  • Lumbar spinal canal stenosis confirmed by imaging or suspected clinically (e.g., neurogenic claudication)
  • Lower limb muscle strength <4/5 according to the Medical Research Council (MRC) scale
  • Use of analgesic medications other than paracetamol during the study period
  • Physical therapy treatment for low back or radicular pain within the past 3 months
  • Contraindications to physical therapy modalities or Tecar therapy
  • Any previous lumbar spine surgery, or interventional spinal procedures within the last 6 months
  • Pregnancy, malignancy, or systemic neurological or rheumatologic disease
  • Advanced spinal or lower extremity deformities (e.g., scoliosis >20°, grade 3-4 spondylolisthesis, vertebral fracture, advanced coxarthrosis)
  • Inability to complete the intervention protocol or follow-up assessments

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Conventional Physical Therapy

Participants in this group will receive conventional physical therapy consisting of hot pack, continuous ultrasound therapy, and transcutaneous electrical nerve stimulation (TENS) applied to the lumbar region. Treatments will be administered five times per week for two weeks (10 sessions). Participants will also receive standardized postural education and a home exercise program.

Conventional physical therapy will include a combination of hot pack, continuous ultrasound therapy, and transcutaneous electrical nerve stimulation (TENS) applied to the lumbar region. Treatment sessions will be conducted five times per week for two weeks. Participants will also receive standardized postural education and a home exercise program.

実験的:Tecar Therapy

Participants in this group will receive Tecar therapy in addition to standardized base physical therapy consisting of hot pack and TENS. Tecar therapy will be applied to the lumbar paraspinal region and gluteal muscles using capacitive and resistive modes with adjustable energy output. Sessions will be performed three times per week for two weeks. Participants will also receive standardized postural education and a home exercise program.

Tecar therapy (Transfer of Energy Capacitive and Resistive) will be applied using capacitive and resistive modes to the lumbar paraspinal region and gluteal muscles. Energy output will be adjusted to approximately 50-70% of the device capacity to achieve a comfortably warm sensation. Each session will last approximately 25 minutes and will be performed three times per week for two weeks. All applications will be delivered using a hypothermic electrode head.

偽コンパレータ:Arm Title

Participants in this group will receive sham Tecar therapy in addition to standardized base physical therapy consisting of hot pack and TENS. The sham procedure will follow the same protocol as the active Tecar therapy, including identical electrode contact and treatment duration, but the device will be set to zero energy output, preventing any thermal or electrical effect. Participants will also receive standardized postural education and a home exercise program.

Sham Tecar therapy will be delivered using the same device, electrode head, treatment duration, and therapist contact as the active Tecar therapy protocol. However, the device will be set to zero intensity output, preventing the delivery of electromagnetic energy or heat. This procedure is designed to mimic the active intervention while providing no therapeutic effect.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Radicular Leg Pain Intensity (Visual Analog Scale, VAS)
時間枠:Baseline to Week 2

Change from baseline to Week 2 in average radicular leg pain over the previous 7 days, measured on a 10-cm VAS (0 = no pain, 10 = worst imaginable pain).

Baseline to Week 2

二次結果の測定

結果測定
メジャーの説明
時間枠
Low Back Pain Intensity (VAS)
時間枠:Baseline, Week 2, Week 6, and Week 12

Average low back pain over the previous 7 days, measured on a 10-cm VAS.

Baseline, Week 2, Week 6, and Week 12
Radicular Leg Pain Intensity (VAS) at Follow-up
時間枠:Baseline, Week 6, and Week 12

Average radicular leg pain over the previous 7 days, measured on a 10-cm VAS.

Baseline, Week 6, and Week 12
Neuropathic Pain Characteristics (PainDETECT Questionnaire)
時間枠:Baseline, Week 2, Week 6, and Week 12

Neuropathic pain features will be assessed using the PainDETECT Questionnaire, a validated self-report instrument ranging from -1 to 38 points. Higher scores indicate a greater likelihood of neuropathic pain components.

Baseline, Week 2, Week 6, and Week 12
Functional Disability (Oswestry Disability Index)
時間枠:Baseline, Week 2, Week 6, and Week 12

ODI version 2.0, percentage score from 0 to 100; higher scores indicate greater disability.

Baseline, Week 2, Week 6, and Week 12
Lumbar Mobility (Modified-Modified Schober Test)
時間枠:Baseline, Week 2, Week 6, and Week 12

Lumbar spine mobility will be assessed using the Modified-Modified Schober Test. The distance between two skin marks placed over the lumbar spine will be measured during maximal forward flexion.

Baseline, Week 2, Week 6, and Week 12
Nerve Root Irritability (Straight Leg Raise Test)
時間枠:Baseline, Week 2, Week 6, and Week 12

The Straight Leg Raise (SLR) test will be used to assess nerve root irritability. The angle at which radicular pain is reproduced during passive leg elevation will be measured using a goniometer.

Baseline, Week 2, Week 6, and Week 12
Rescue Medication Consumption
時間枠:Weeks 1, 2, 6, and 12

Total paracetamol intake (mg/week).

Weeks 1, 2, 6, and 12
Exercise Adherence
時間枠:Weeks 1, 2, 6, and 12

Self-reported percentage of target home exercise sessions completed.

Weeks 1, 2, 6, and 12

その他の成果指標

結果測定
メジャーの説明
時間枠
Treatment Credibility and Expectancy
時間枠:Baseline

Credibility/Expectancy Questionnaire, administered before the first treatment session.

Baseline
Perceived Treatment Allocation
時間枠:Week 2

Participant belief about the treatment received (active, control, or do not know), TECAR and sham groups only.

Week 2

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Ertan Yilmaz, MD、Izmir City Hospital

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年4月15日

一次修了 (推定)

2028年4月15日

研究の完了 (推定)

2028年12月15日

試験登録日

最初に提出

2026年3月14日

QC基準を満たした最初の提出物

2026年3月14日

最初の投稿 (実際)

2026年3月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月11日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 2024-KAEK-23

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data will not be publicly shared due to institutional data protection policies and privacy regulations. Only aggregated data will be reported in scientific publications.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。